Sanofi
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNY research report →
Companywww.sanofi.com
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
- CEO
- Olivier Charmeil
- IPO
- 2002
- Employees
- 82,878
- HQ
- Paris, FR
Price Chart
Valuation
- Market Cap
- $107.58B
- P/E
- 8.91
- P/S
- 1.56
- P/B
- 1.27
- EV/EBITDA
- 9.78
- Div Yield
- 5.37%
Profitability
- Gross Margin
- 71.62%
- Op Margin
- 25.09%
- Net Margin
- 17.59%
- ROE
- 14.41%
- ROIC
- 11.66%
Growth & Income
- Revenue
- $46.72B · 5.49%
- Net Income
- $7.81B · 40.52%
- EPS
- $3.20 · 45.79%
- Op Income
- $9.60B
- FCF YoY
- 72.34%
Performance & Tape
- 52W High
- $53.36
- 52W Low
- $42.33
- 50D MA
- $45.49
- 200D MA
- $47.70
- Beta
- 0.28
- Avg Volume
- 3.31M
Get TickerSpark's AI analysis on SNY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SNY Coverage
View all →
Sanofi (SNY): Dupixent Drives a Buy Case
Sanofi is becoming a more focused biopharma compounder, led by Dupixent growth, vaccine strength, and expanding launch sales. The stock looks inexpensive versus its cash generation and earnings power.
Sanofi (SNY) drops 5% on downgrade and ex-dividend
Sanofi (SNY) drops about 5% after a Morgan Stanley downgrade and ex-dividend pressure, even as the drugmaker posted strong Q1 results. The selloff reflects investor concern over growth durability, pipeline depth, and reliance on Dupixent rather than a fresh operating setback.
Want a deeper read on SNY?
Generate a full analyst-grade report — bull / bear case, price targets, valuation depth, and a complete financial breakdown.